Xenon Pharmaceuticals (XENE) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.11

Estimate

-$1.16

Surprise

+3.9%

Score today

5.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Xenon Pharmaceuticals (XENE) reported a narrower loss than forecast — adjusted EPS of -$1.11 against the -$1.16 estimate (a 3.9% beat on a still-unprofitable quarter).

TrendMatrix currently rates XENE Sell at 5.5/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +3.9% surprise compares with a -0.2% four-quarter average. Next scheduled report: 2026-11-09.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$38.23

Price target

$64.58

Stop

$35.77

Upside to target

+68.9%

Reward-to-risk

5.4:1

Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$3.64B

P/E (fwd)

-8.0

52-week range

$33.38–$72.66

Off 52-week high

47.4%

RSI (14)

73

Volume vs avg

0.91×

Score today

5.5/10